GlassScriptPhysician profile
Janice Desir
NPI 1811161490
$1,987.22
in general payments reported to CMS, 2019-2025
22 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $377 · 2021: $187 · 2022: $176 · 2023: $365 · 2024: $171 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $405.89 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Vifor Pharma, INC. | $186.09 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $178.10 | 2019-2024 | Lokelma |
| Otsuka America Pharmaceutical, INC. | $165.54 | 2019-2020 | |
| Lilly USA, LLC | $149.61 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $131.78 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $117.40 | 2024-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $92.78 | 2021-2023 | Velphoro |
| Horizon Therapeutics Plc | $77.94 | 2020 | |
| Aurinia Pharma U.S., INC. | $70.75 | 2021-2023 | Lupkynis |
| Akebia Therapeutics INC | $65.18 | 2020-2025 | Vafseo |
| Novo Nordisk INC | $60.05 | 2022-2025 | Ozempic |
| Scpharmaceuticals INC. | $53.09 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.29 | 2022-2025 | |
| Exact Sciences Corporation | $33.00 | 2025 | The Cologuard Plus Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $27.47 | 2023 | Crysvita |
| Novartis Pharmaceuticals Corporation | $25.59 | 2023 | |
| Glaxosmithkline, LLC. | $25.05 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.21 | 2025 | Jardiance |
| Shield Therapeutics INC | $20.78 | 2023 | Accrufer |
| Ardelyx, INC. | $18.22 | 2024 | Ibsrela |
| Dexcom, INC. | $13.41 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Desir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.